In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?

Moderna’s mRESVIA is the first FDA-approved mRNA therapy designed to prevent respiratory syncytial virus (RSV) in adults 60 and over. The EU, Norway, Iceland, and Qatar have also approved it.

Moderna's trailing-12-month revenue is just ... And despite widespread outbreaks of respiratory syncytial virus (RSV), the recent approval of its RSV vaccine has also not moved the needle much.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Through the first nine months of 2024, Moderna's revenue of $2.3 billion represents a 44% decline year over year. This figure includes a mere $10 million in sales of the new RSV vaccine following ...

Moderna CEO Stephane Bancel commented, "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and continued to adapt our COVID-19 business for the endemic setting.